The pleural fluid lactate dehydrogenase /adenosine deaminase and pleural fluid adenosine deaminase /serum C-Reactive Protein ratios for differentiating between Tuberculosis and other causes in a sample of Iraqi patients

SummaryIntroduction. With the ongoing COVID-19 pandemic, finding new treatments is an extremely important issue. The effectiveness of heliox was previously demonstrated in the complex treatment of patients with various bron-chopulmonary pathologies. Therefore, this method has been recommended for the treatment of pneumonia associated with COVID-19. Purpose. To study the safety and efficacy of inhaled heliox therapy in the treatment of pneumonia in COVID-19. Materials and methods. A sing-le-center prospective study was carried out for the period from 01.12.2020 to 15.02.2021. The study included 91 pa-tients. The patients were divided into two groups: group 1 (using heliox) included 46 people, and group 2 (con-trol) — 45. Inhalations of a heated oxygen-helium mixture heliox (70% helium, 30% oxygen) were carried out using “Ingalit-B2-01” inhaler. Objective (saturation, O2 flow) and laboratory parameters (lactate dehydrogenase, C-reactive protein), as well as chest organs CT data were studied. Differences between groups were determined using the χ2 test, as well as the Mann–Whitney U-test. The p value <0.05 was considered significant. Results. In group 1, side effects developed in 5 (11.3%) patients. These patients refused to further participate in the study. Final number of patients in group 1 — 41. Among patients of group 1, there was a tendency towards a more rapid normalization of lactate dehydrogenase and C-reactive protein, as well as a decrease in oxygen dependence. In group 1, according to CT data, no progression of pneumonia was recorded. In group 2, progression was observed in 6 (13.3%) patients. The overall effectiveness of treatment among patients in group 1 was 100%, among patients in group 2 — 86.7%. The differences between the groups are statistically sig-nificant (p=0.02). Conclusion. The use of inhalations with a heated oxygen-helium mixture heliox (30% oxygen, 70% helium) has shown its effectiveness and safety in the treatment of viral pneumonia (CT1- 2) associated with COVID-19.

Download Full-text

Pleural fluid interleukin-8 and C-reactive protein for discriminating complicated non-purulent from uncomplicated parapneumonic effusions

Respirology ◽

10.1111/j.1440-1843.2007.01189.x ◽

2008 ◽

Vol 13 (1) ◽

pp. 58-62 ◽

Cited By ~ 24

Author(s):

José M. PORCEL ◽

Carlos GALINDO ◽

Aureli ESQUERDA ◽

Javier TRUJILLANO ◽

Agustín RUIZ-GONZÁLEZ ◽

...

Keyword(s):

Pleural Fluid ◽

Interleukin 8 ◽

C Reactive Protein ◽

Reactive Protein

Download Full-text

Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd012645 ◽

2017 ◽

Cited By ~ 4

Author(s):

Oluyemi Komolafe ◽

Stephen P Pereira ◽

Brian R Davidson ◽

Kurinchi Selvan Gurusamy

Keyword(s):

Lactate Dehydrogenase ◽

Pancreatic Necrosis ◽

C Reactive Protein ◽

Reactive Protein

Download Full-text

The role of IL-6 receptor inhibitor treatment in critical patient monitoring with COVID-19

10.22514/sv.2021.068 ◽

2021 ◽

Keyword(s):

Intensive Care Unit ◽

Intensive Care ◽

Lactate Dehydrogenase ◽

Critically Ill ◽

Critically Ill Patients ◽

C Reactive Protein ◽

Reactive Protein ◽

Group 2 ◽

D Dimer

Objectives: The COVID-19 disease can manifest itself with acute respiratory distress syndrome, renal failure, and septic shock in critically ill patients. There are opinions that there is a correlation between high IL-6 levels and disease severity. In our intensive care unit, we evaluated the changes in the laboratory data and radiological involvement severity of our patients who underwent tocilizumab treatment and examined the appropriate laboratory parameter in the treatment follow-up and its effect on survival. Methods: In the critical patient follow-up of COVID-19, 17 of the 23 patients treated with tocilizumab had a mortal course (Group 1) and the remaining 6 (Group 2) were. The C-reactive protein, lactate dehydrogenase, IL-6, D-dimer, procalcitonin, albumin, and ferritin values, which were routinely screened in our clinic on the day of tocilizumab treatment and the 5th day after, were recorded. Both the change between the two groups and the change between days 1 and 5 were analyzed. Results: A total of 23 patients (55.35 ± 13.31 years) were included in the study. The computed tomography severity score assessed at the intensive care unit admission was statistically significantly higher in Group 2. The procalcitonin and lactate dehydrogenase values measured on day 5 after tocilizumab were significantly lower in Group 2. On the 5th day after treatment, the levels of C-reactive protein, ferritin, chest X-rays, IL-6 and D-dimer statistically significantly changed compared to the first day of the treatment. In correlation with the decrease in PCT as of the 5th day after tocilizumab administration, an increasing tendency was observed in 28-day survival. Conclusion: This study demonstrated that tocilizumab treatment may positively contribute to the treatment by decreasing cytokine levels. PCT and LDH follow-up before and after treatment in critically ill patients who are receiving tocilizumab treatment can give an idea about survival.

Download Full-text

Study of serum adenosine deaminase activity and c-reactive protein in patients of rheumatoid arthritis

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v11i4.4724 ◽

2020 ◽

Vol 11 (4) ◽

pp. 7990-7993

Author(s):

Sangeetha R ◽

Ramesh Raju K A P ◽

Hemapriya S ◽

Suganthi V ◽

Panneerselvam P

Keyword(s):

Rheumatoid Arthritis ◽

Adenosine Deaminase ◽

Treatment Plan ◽

Colorimetric Method ◽

Disease Score ◽

C Reactive Protein ◽

Positive Correlation ◽

Reactive Protein ◽

Adenosine Deaminase Activity

Rheumatoid arthritis (RA) is a chronic disease that causes inflammatory synovitis. The treatment plan of RA includes reducing inflammation and improving the quality of life. Hence, understanding the role of Adenosine deaminase (ADA) and C-reactive protein helps for a better plan of treatment. The present study was undertaken to determine the serum ADA activity and CRP in RA patients and correlate with the severity of the progression of the disease. 25 patients diagnosed with RA as per 2010 ACR/EULAR criteria and 25 age and sex matched healthy controls were included in the study after informed consent. Blood samples were collected from all the subjects after an overnight fast, serum separated was analyzed immediately for Adenosine deaminase(ADA) activity measured using colorimetric method of Guisti and Galanti. Disease score, C-reactive protein, RA factor, ADA and ESR were significantly higher in cases when compared with controls. Significant positive correlation was present between the disease score and C-reactive protein, RA factor among cases. A positive correlation was observed between the disease score and ADA, but it was not statistically significant among cases.

Download Full-text

Use of C-reactive protein level in diagnosis of tubercular pleural effusion

Journal of Kathmandu Medical College ◽

10.3126/jkmc.v8i1.25264 ◽

2019 ◽

Vol 8 (1) ◽

pp. 20-23

Author(s):

Subash Pant ◽

Sanjeet Krishna Shrestha ◽

Lucky Sharma ◽

Bibechana Shrestha

Keyword(s):

Pleural Effusion ◽

Pleural Fluid ◽

Protein Level ◽

College Teaching ◽

C Reactive Protein ◽

Biochemical Tests ◽

Cross Sectional ◽

Female Ratio ◽

Protein Levels ◽

Reactive Protein

Background: C-reactive protein in both pleural fluid and serum has been found to be higher in tubercular pleural effusion than in other causes of pleural effusion. Objectives: The main aim of this study was to find out the diagnostic value of C-reactive protein in patients withlymphocytic pleural effusion. Methodology: A cross-sectional study was conducted in 90 patients with pleural effusion who underwent thoracocentesis at Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal. The complete biochemical tests of pleural fluid and serum were performed. The C-reactive protein concentrations of both pleural fluid and serum were then measured from samples from patients with lymphocytic exudative pleural effusion. Results: Ninety patients with exudative lymphocytic pleural effusion were included. Male patients were 56 (62.2%) and female were 34 (37.8%) with the male to female ratio of 1.64. Mean age of the patients was 51±21.54 (Mean ± Standard Deviation). The pleural fluid C-reactive protein levels in tubercular pleural effusion were higher (48.87±24.19 mg/dl) compared to non-tubercular group (38.30±17 mg/dl; p<0.001). Similarly, the serum fluid C-reactive protein levels in tubercular pleural effusion were higher (29.60±13mg/dl) compared to non-tubercular group (18.14±9.2mg/dl; p< 0.001). The sensitivity of pleural fluid C-reactive protein level in diagnosing tubercular pleural effusion was 86%. Conclusion: Simple and inexpensive test like C-reactive protein is useful in the diagnostic workup of lymphocytic pleural effusions. High C-reactive protein levels are very suggestive of tubercular pleural effusion.

Download Full-text